Etomidate

CLINICAL USE


Induction of anaesthesia

DOSE IN NORMAL RENAL FUNCTION

150–300 mcg/kg

PHARMACOKINETICS

  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :244.3
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :76
  • %Excreted unchanged in urine &nbsp &nbsp : 2
  • Volume of distribution (L/kg) &nbsp &nbsp &nbsp :2–4.5
  • half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :4–5/Unchanged

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function

  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Unknown dialysability. Dose as in normal renal function
  • HDF/high flux &nbsp :Unknown dialysability. Dose as in normal renal function
  • CAV/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugsAdrenergic neurone blockers: enhanced hypotensive effectAntihypertensives: enhanced hypotensive effect
  • Antidepressants: avoid MAOIs for 2 weeks before surgery; increased risk of arrhythmias and hypotension with tricyclics
  • Antipsychotics: enhanced hypotensive effect

    ADMINISTRATION

    Reconstition

    Route

    Intravenous injection only

    Rate of Administration

    Comments

    OTHER INFORMATION

    In cases of adrenocortical gland dysfunction and during very long surgical procedures, a prophylactic cortisol supplement may be required (e.g. 50–100 mg hydrocortisone)